Trial Search Results

Reducing Lung CongestIon Symptoms in Advanced Heart Failure

The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical outcomes in patients with New York Heart Association (NYHA) functional Class II, Class III, or ambulatory Class IV heart failure (HF), irrespective of left ventricular ejection fraction, who at baseline are treated with guideline-directed drug and device therapies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

V-Wave Ltd

Stanford Investigator(s):


  • Device: V-Wave Interatrial Shunt
  • Other: Control




Main Inclusion Criteria:

   - Both heart failure with reduced ejection fraction (HFrEF) and heart failure with
   preserved ejection fraction (HFpEF) patients

   - NYHA Class II, Class III, or ambulatory Class IV HF

   - Receiving guideline directed medical and device therapy (GDMT) for heart failure

   - For NYHA Class III and ambulatory Class IV, at least one prior hospitalization for
   heart failure within the last year or elevated BNP level of at least 300 pg/ml or
   NT-proBNP level of at least 1,500 pg/ml. BNP/NT-ProBNP levels corrected for BMI

   - For NYHA Class II, must have both hospitalization and elevated BNP levels as above

Main Exclusion Criteria:

   - Systolic blood pressure <90 or >160 mmHg

   - Presence of Intracardiac thrombus

   - Pulmonary hypertension with PASP of ≥70 mm/Hg or PVR > 4 WU

   - Significant RV dysfunction - TAPSE <12mm or RVFAC ≤25%

   - Left Ventricular End-Diastolic Diameter (LVEDD) >8cm

   - Moderate to severe aortic or mitral stenosis

   - Stroke or TIA or DVT within the last 6 months

   - eGFR <25 ml/min/1.73 m^2

   - Anatomical anomaly on TEE or ICE that precludes implantation of Shunt across fossa
   ovalis (FO) of the interatrial septum

   - Inadequate vascular access for implantation of shunt, e.g. femoral venous access for
   transseptal catheterization and inferior vena cava (IVC) is not patent

   - Hemodynamic heart rhythm, or respiratory instability at time of Final Exclusion

Ages Eligible for Study

18 Years - 99 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jeffrey Teuteberg, MD